I am currently Professor of Pharmacology and Psychiatry at the University of Texas Health Science Center at San Antonio where I have spent >75% of my time and effort on research supported by 5 R01s and a K02 award from NIDA. My goal in submitting a Research Career Award (RCA, K05) is to allow me to continue devoting >75% of my time to drug abuse research and training. Support under the RCA mechanism (K02) for the past 10 years has allowed me to avoid most teaching and service to the University and instead to devote my time to developing a preclinical research laboratory that focuses on the behavioral and pharmacologic determinants of drug abuse, dependence and withdrawal. I also have had the freedom to pursue several new and productive collaborations on this campus and elsewhere and I have spent considerable time training and promoting the careers of young researchers. This revised application is submitted in response to PA-00-21 """"""""Senior Scientist Award."""""""" The major scientific goals of my career development during the period for which support is requested are the following: to understand the neuropharmacologic mechanisms that mediate the dependence and withdrawal effects of opioids and benzodiazepines;to identify the mechanisms that contribute to the therapeutic as well as abuse related effects of GHB and related compounds, in part, through the discovery of new compounds;to determine how insulin-receptor pathways in brain modulate behavioral actions of stimulants;to expand research capabilities of our group to include in vivo voltammetry, genomics, and behavioral studies in mice;and to continue a major commitment to collaborations and training of young investigators in drug abuse research. Major goals for the next several years also include submission of an institutional pre- and postdoctoral training grant, work towards obtaining resources for the expansion and further renovation of our laboratory facilities, in part through the establishment of a Center of Excellence in Behavioral Pharmacology, and continued recruitment of students, particularly underrepresented minorities from South Texas, to our graduate program in pharmacology, especially the behavioral sciences. My Chairman, Dr. Frazer, and the Administration are committed to the continued growth of drug abuse research at this institution, as evidenced by their financial commitments through the recruitment of a new investigators and providing matching funding for the renovation of laboratory animal facilities. This award will allow me to continue spending the majority of my time on NIH-sponsored research and on the expansion of drug abuse research and training at the Health Science Center.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Scientist Award (K05)
Project #
5K05DA017918-05
Application #
7581002
Study Section
Human Development Research Subcommittee (NIDA)
Program Officer
Thomas, David A
Project Start
2005-03-01
Project End
2010-09-29
Budget Start
2009-03-01
Budget End
2010-09-29
Support Year
5
Fiscal Year
2009
Total Cost
$116,640
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Pharmacology
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Collins, Gregory T; France, Charles P (2018) Effects of lorcaserin and buspirone, administered alone and as a mixture, on cocaine self-administration in male and female rhesus monkeys. Exp Clin Psychopharmacol 26:488-496
Maguire, David R; France, Charles P (2018) Antinociceptive effects of mixtures of mu opioid receptor agonists and cannabinoid receptor agonists in rats: Impact of drug and fixed-dose ratio. Eur J Pharmacol 819:217-224
Minervini, Vanessa; Lu, Hannah Y; Padarti, Jahnavi et al. (2018) Interactions between kappa and mu opioid receptor agonists: effects of the ratio of drugs in mixtures. Psychopharmacology (Berl) 235:2245-2256
Collins, Gregory T; Gerak, Lisa R; France, Charles P (2018) The behavioral pharmacology and therapeutic potential of lorcaserin for substance use disorders. Neuropharmacology 142:63-71
Minervini, Vanessa; France, Charles P (2018) Effects of morphine/CP55940 mixtures on an impulsive choice task in rhesus monkeys. Behav Pharmacol 29:60-70
Minervini, Vanessa; Dahal, Sujata; France, Charles P (2017) Behavioral Characterization of ? Opioid Receptor Agonist Spiradoline and Cannabinoid Receptor Agonist CP55940 Mixtures in Rats. J Pharmacol Exp Ther 360:280-287
Gerak, Lisa R; Collins, Gregory T; France, Charles P (2016) Effects of Lorcaserin on Cocaine and Methamphetamine Self-Administration and Reinstatement of Responding Previously Maintained by Cocaine in Rhesus Monkeys. J Pharmacol Exp Ther 359:383-391
Maguire, D R; Henson, C; France, C P (2016) Daily morphine administration increases impulsivity in rats responding under a 5-choice serial reaction time task. Br J Pharmacol 173:1350-62
Lamb, R J; Maguire, David R; Ginsburg, Brett C et al. (2016) Determinants of choice, and vulnerability and recovery in addiction. Behav Processes 127:35-42
Collins, Gregory T; Abbott, Megan; Galindo, Kayla et al. (2016) Discriminative Stimulus Effects of Binary Drug Mixtures: Studies with Cocaine, MDPV, and Caffeine. J Pharmacol Exp Ther 359:1-10

Showing the most recent 10 out of 106 publications